Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12057431 | 0.99 | TSHR (0.41) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL584884 | 0.92 | TSHR (0.47) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL12633103 | 0.90 | MLNR (0.38) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL14806865 | 0.90 | TSHR (0.41) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL27976875 | 0.89 | TSHR (0.41) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| Zinc Ion SCHEMBL27976882 | 0.89 | TSHR (0.41) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| SCHEMBL27976881 | 0.89 | TSHR (0.41) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| Bromide SCHEMBL14806853 | 0.88 | TSHR (0.40) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| Bromide SCHEMBL14806851 | 0.88 | TSHR (0.40) | CYP1A2CYP19A1CYP2C9CYP2C19TSHR | |
| Hydrochloric Acid SCHEMBL585452 | 0.87 | TERT (0.44) | CYP1A2CYP19A1CYP2C9CYP2C19TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | CHRM2 2736/4885CHRM1 1754/4885CHRM3 3127/4885 |
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | CHRM2 2709/4885CHRM1 2458/4885CHRM3 3318/4885 |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | CHRM2 1988/4885CHRM1 1911/4885CHRM3 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.